Initial Testing of JNJ-26854165 (Serdemetan) by the Pediatric Preclinical Testing Program

JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC(50) (0.85 µM) than the remaining cell lines. In vivo JNJ-26854165 induc...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pediatr Blood Cancer
Hlavní autoři: Smith, Malcolm A., Gorlick, Richard, Kolb, E. Anders, Lock, Richard, Carol, Hernan, Maris, John M., Keir, Stephen T., Morton, Christopher L., Reynolds, C. Patrick, Kang, Min H., Arts, Janine, Bashir, Tarig, Janicot, Michel, Kurmasheva, Raushan T., Houghton, Peter J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4504194/
https://ncbi.nlm.nih.gov/pubmed/21922647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.23319
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky